Equity Overview
Price & Market Data
Price: $4.42
Daily Change: -$0.29 / 6.56%
Range: $4.28 - $4.93
Market Cap: $255,714,448
Volume: 533,507
Performance Metrics
1 Week: -14.99%
1 Month: 7.75%
3 Months: -34.40%
6 Months: -65.74%
1 Year: -63.85%
YTD: -45.17%
Company Details
Employees: 168
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Alumis Inc., a clinical stage biopharmaceutical company, focuses on identifying, acquiring, and accelerating the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises of ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor which is in Phase 3 clinical trials for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; A-005, a central nervous system-penetrant allosteric TYK2 inhibitor which is in Phase 1 clinical trials for neuroinflammatory and neurodegenerative diseases; and interferon regulatory factor 5 (IRF5) which is in preclinical phase to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.